Lijun Ma1, Jasmin Divers2, Barry I Freedman1. 1. Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC. 2. Division of Public Health Sciences, Department of Biostatistical Sciences.
Abstract
BACKGROUND: An improved understanding of the pathogenesis in apolipoprotein L1 (APOL1) gene-associated chronic kidney disease (CKD) arose from observations in kidney transplantation. APOL1 genotyping could soon improve the safety of living kidney donation in individuals with recent African ancestry and alter the allocation of deceased donor kidneys. METHODS: This article reviews the potential mechanisms that underlie development of APOL1-associated nephropathy. Roles for circulating APOL1 protein versus intrinsic renal expression of APOL1 are discussed, as well as the requirement for modifying genetic and/or environmental factors. RESULTS: Abundant evidence supports local kidney production of APOL1 renal-risk variant protein in the development of nephropathy; this is true in both native kidney disease and after renal transplantation. Only a minority of kidneys from individuals with APOL1 high-risk genotypes will develop CKD or manifest shorter renal allograft survival after transplantation. Therefore, modifying factors that explain why only a subset of kidneys develops nephropathy remain critical to identify. It appears likely that environmental exposures, as opposed to major APOL1-second gene interactions, will prove to be stronger modifiers of the risk for nephropathy. CONCLUSIONS: The evolving understanding of the pathogenesis in APOL1-associated nephropathy will identify biomarkers predicting nephropathy in individuals at high genetic risk and lead to novel therapies to prevent or slow native CKD progression and prolong survival of transplanted kidneys. In the interim, the National Institutes of Health-sponsored "APOL1 Long-term Kidney Transplantation Outcomes" Network will determine whether APOL1 genotyping in individuals with recent African ancestry improves outcomes and safety in kidney transplantation.
BACKGROUND: An improved understanding of the pathogenesis in apolipoprotein L1 (APOL1) gene-associated chronic kidney disease (CKD) arose from observations in kidney transplantation. APOL1 genotyping could soon improve the safety of living kidney donation in individuals with recent African ancestry and alter the allocation of deceased donor kidneys. METHODS: This article reviews the potential mechanisms that underlie development of APOL1-associated nephropathy. Roles for circulating APOL1 protein versus intrinsic renal expression of APOL1 are discussed, as well as the requirement for modifying genetic and/or environmental factors. RESULTS: Abundant evidence supports local kidney production of APOL1 renal-risk variant protein in the development of nephropathy; this is true in both native kidney disease and after renal transplantation. Only a minority of kidneys from individuals with APOL1 high-risk genotypes will develop CKD or manifest shorter renal allograft survival after transplantation. Therefore, modifying factors that explain why only a subset of kidneys develops nephropathy remain critical to identify. It appears likely that environmental exposures, as opposed to major APOL1-second gene interactions, will prove to be stronger modifiers of the risk for nephropathy. CONCLUSIONS: The evolving understanding of the pathogenesis in APOL1-associated nephropathy will identify biomarkers predicting nephropathy in individuals at high genetic risk and lead to novel therapies to prevent or slow native CKD progression and prolong survival of transplanted kidneys. In the interim, the National Institutes of Health-sponsored "APOL1 Long-term Kidney Transplantation Outcomes" Network will determine whether APOL1 genotyping in individuals with recent African ancestry improves outcomes and safety in kidney transplantation.
Authors: Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak Journal: Science Date: 2010-07-15 Impact factor: 47.728
Authors: A M Reeves-Daniel; J A DePalma; A J Bleyer; M V Rocco; M Murea; P L Adams; C D Langefeld; D W Bowden; P J Hicks; R J Stratta; J-J Lin; D F Kiger; M D Gautreaux; J Divers; B I Freedman Journal: Am J Transplant Date: 2011-04-12 Impact factor: 8.086
Authors: Atanu K Khatua; Amber M Cheatham; Etty D Kruzel; Pravin C Singhal; Karl Skorecki; Waldemar Popik Journal: Am J Physiol Cell Physiol Date: 2015-04-29 Impact factor: 4.249
Authors: E P Pires; C V Bernardino-Vallinoto; D M Alves; S R C Migone; L F A Machado; M O G Ishak; R Ishak; I M V Cayres-Vallinoto; A C R Vallinoto Journal: Transpl Infect Dis Date: 2011-03-17 Impact factor: 2.228
Authors: Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian Journal: J Am Soc Nephrol Date: 2013-11-14 Impact factor: 10.121
Authors: Nidhi Gupta; Xinhua Wang; Xiaohui Wen; Paul Moran; Maciej Paluch; Philip E Hass; Amy Heidersbach; Benjamin Haley; Daniel Kirchhofer; Randall J Brezski; Andrew S Peterson; Suzie J Scales Journal: J Am Soc Nephrol Date: 2020-08-06 Impact factor: 10.121
Authors: Pepe M Ekulu; Agathe B Nkoy; Oyindamola C Adebayo; Orly K Kazadi; Michel N Aloni; Fanny O Arcolino; Rene M Ngiyulu; Jean-Lambert E Gini; François B Lepira; Lamberthus P Van den Heuvel; Elena N Levtchenko Journal: Pediatr Nephrol Date: 2020-04-06 Impact factor: 3.714
Authors: Elmi Muller; Francois C J Botha; Zunaid A Barday; Kathryn Manning; Peter Chin-Hong; Peter Stock Journal: Transplantation Date: 2021-07-01 Impact factor: 5.385
Authors: Courtenay M Holscher; Tanveen Ishaque; Christine E Haugen; Kyle R Jackson; Jacqueline M Garonzik Wang; Yifan Yu; Fawaz Al Ammary; Dorry L Segev; Allan B Massie Journal: Transplantation Date: 2020-03 Impact factor: 5.385
Authors: Yanni Li; Lianne M Nieuwenhuis; Brendan J Keating; Eleonora A M Festen; Vincent E de Meijer Journal: Transplantation Date: 2021-12-28 Impact factor: 5.385
Authors: Ashira Blazer; Yingzhi Qian; Martin Paul Schlegel; Huda Algasas; Jill P Buyon; Ken Cadwell; Michael Cammer; Sean P Heffron; Feng-Xia Liang; Shilpi Mehta-Lee; Timothy Niewold; Sara E Rasmussen; Robert M Clancy Journal: Front Genet Date: 2022-09-27 Impact factor: 4.772
Authors: Mark Ultsch; Michael J Holliday; Stefan Gerhardy; Paul Moran; Suzie J Scales; Nidhi Gupta; Francesca Oltrabella; Cecilia Chiu; Wayne Fairbrother; Charles Eigenbrot; Daniel Kirchhofer Journal: Commun Biol Date: 2021-07-27